Published in Health Business Week, February 4th, 2005
The company will use proceeds from this Series B financing round to expand applications for its new MicroMatrix ingredient delivery technology, continue development of new disease prevention products, and to build sales of its DHA and ARA nutritional products.
ABN's proprietary and unique MicroMatrix technology allows the encapsulation of active ingredients such as probiotic bacteria for the extension of food applications, including use in infant formula.
ABN's technology makes possible the oral delivery of a wide...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week